Examples of 'lomitapide' in a sentence
Meaning of "lomitapide"
lomitapide (noun): A drug used in the treatment of high cholesterol levels, specifically in patients with a genetic condition that causes high cholesterol
Show more definitions
- An investigational drug for the treatment of familial hypercholesterolemia.
How to use "lomitapide" in a sentence
Basic
Advanced
lomitapide
Lomitapide increases the plasma concentrations of warfarin.
No clinically meaningful increase in lomitapide exposure was observed.
Lomitapide increases plasma concentrations of statins.
Lojuxta contains the active substance called lomitapide.
Effects of lomitapide on other medicinal products.
These changes are secondary to the mechanism of action of lomitapide.
It is not known whether lomitapide is excreted into human milk.
Other lipid modifying agents lomitapide.
The use of alcohol during lomitapide treatment is not recommended.
Administration with food may increase exposure to lomitapide.
Lomitapide was not mutagenic or genotoxic in a battery of in vitro and in vivo studies.
The active substance is lomitapide.
Effects on lomitapide levels.
Lojuxta is a medicine that contains the active substance lomitapide.
The effect of concomitant administration of lomitapide with other hepatotoxic medicine is unknown.
See also
To evaluate the occurrence of the following in patients treated with lomitapide.
Lomitapide does not inhibit breast cancer resistance protein BCRP.
Haemodialysis is unlikely to be beneficial given that lomitapide is highly protein bound.
Lomitapide approved by the EMA.
The long term consequences of hepatic steatosis associated with lomitapide treatment are unknown.
Each hard capsule contains lomitapide mesylate equivalent to 5 mg lomitapide.
Upon multiple dosing Cmax and AUC increased in approximate proportion to lomitapide dose.
The terminal half-life of lomitapide was not affected.
Consequently, this would reduce the effect of lomitapide.
Lovastatin, simvastatin and lomitapide to lower cholesterol levels.
Post-marketing reports of dehydration and hospitalisation in patients treated with lomitapide have been reported.
There is limited experience with lomitapide in patients aged 65 years or older.
Recommendation concerning co-administration with Lojuxta no clinically meaningful increase in lomitapide exposure was observed.
In particular, therapy with lomitapide is associated with 8-fold increase in the liver fat content.
Due to CYP3A inhibition by ritonavir, concentrations of lomitapide are expected to increase.
Lomitapide appears to be a sensitive substrate for CYP3A4 metabolism.
Interactions between moderate CYP3A4 inhibitors and lomitapide have not been studied.
In ferrets, lomitapide was both maternally toxic and teratogenic at < 1 times the MRHD.
Weak CYP3A4 inhibitors are expected to increase the exposure of lomitapide when taken simultaneously.
Lomitapide can cause elevations in alanine aminotransferase [ ALT ] and aspartate aminotransferase [ AST ] and hepatic steatosis.
Based on theoretical considerations, Symtuza is expected to increase the exposure of lomitapide when coadministered.
Lomitapide is not a P-gp substrate but does inhibit P-gp.
Based on theoretical considerations, REZOLSTA is expected to increase the exposure of lomitapide when coadministered.
Lomitapide ( used to lower blood cholesterol ) ;.
Lojuxta 5 mg, each hard capsule contains lomitapide mesylate equivalent to 5 mg lomitapide.
Co-administration of a CYP3A4 inducer is expected to reduce the effect of lomitapide.
Inter-individual variability in lomitapide AUC was approximately 50.
Lomitapide is a “ lipid-modifying agent ” which works by blocking the action of “ microsomal triglyceride transfer protein . ”.
In vitro assessment of drug interactions, Lomitapide inhibits CYP3A4.
Concomitant use of ritonavir with lomitapide is contraindicated ( see prescribing information for lomitapide ) ( see section 4.3 ).
Lipid-modifying agents Lomitapide.
Concomitant use of Norvir with lomitapide is contraindicated ( see prescribing information for lomitapide ) ( see section 4.3 ).
Elevations in aminotransferases ( ALT and / or AST ) are associated with lomitapide see section 5.1.
Concomitant use of Kaletra with lomitapide is contraindicated ( see prescribing information for lomitapide ) ( see section 4.3 ).
Lomitapide is extensively metabolised, predominantly by CYP3A4.
